Inhibiteurs

CYH33 methanesulfonate is a PI3Kα inhibitor with IC50 of 5.9 nM; halts breast and NSCLC cell growth, effective against solid tumors.

Oroxin A, a partial PPARγ agonist, activates PPARγ, inhibits α-glucosidase, and has antioxidant properties.

m-PEG12-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

Ppack HCl is a peptide that binds thrombin, inhibiting platelet activation (Ki: 0.24 nM). Used as an anticoagulant and to research clotting and inflammation.

Melarsonyl dipotassium, also known as melarsonic acid dipotassium, is a potent anthelmintic agent with the ability to effectively inhibit parasites.

HJM-561 is a potent and selective EGFR PROTAC with oral bioavailability, capable of overcoming osimertinib-resistant EGFR triple mutations and demonstrating

N2S2-CBMBC, a bromo-benzyl ether, binds to 99mTc for PD-L1 tumor imaging, offering a real-time alternative to immunohistochemistry.

STING agonist-22 (CF501) boosts vaccines by activating STING, inducing IFN-I and cytokines, aiding in SARS-CoV-2 research.

9-Azido-Neu5DAz is a non-natural bifunctional carbohydrates as imaging agent.

Propiram fumarate HClis an orally available Opioid receptors agonist with analgesic activity for the study of musculoskeletal pain.

PROTAC MDM2 Degrader-1 uses PROTAC tech to break down MDM2 with an inhibitor, linker, and E3 ligase ligand.

Yimitasvir, an oral NS5A inhibitor, treats chronic hepatitis C. Used for research.

LH1306 inhibits PD-1/PD-L1 interaction, IC50: 25 nM (HTRF assay); boosts Jurkat cell activation, EC50: 334-4,214 nM.